Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
SYBX vs IMDX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SYBX Captures Overall Composite Edge (34.6 SELL vs 45.5 HOLD), While IMDX Leads 3–2 on Growth & Valuation Pillars
SYBX Overall Winner
6-Pillar Tally: SYBX 2 – 3 IMDX (1 Tie)
Matrix Metrics: SYBX 2 – 5 IMDX
As of Nov 19, 2026, Synlogic, Inc. (SYBX) captures the overall head-to-head institutional edge over Insight Molecular Diagnostics Inc. (IMDX) on higher Unified Composite conviction (34.6/100 SELL vs. 45.5/100 HOLD) after splitting the core matrix 2–5 (led by Profitability & Quality, Options & Positioning), while IMDX wins 3–2 across the 6-pillar growth and valuation breakdown. SYBX trades at $0.56 (N/M Forward P/E, 0.0% operating margin) versus IMDX at $1.66 (N/M Forward P/E, -1883.2% operating margin).
- Composite vs. Pillar Nuance: While IMDX currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. SYBX 34.6/100 SELL), SYBX captures the overall institutional head-to-head verdict (2–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -1883.2% operating margin) and revenue trajectory (-100.0% vs. +115.0% YoY).
- Technical & Structure Timing Caution: SYBX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 16.7); meanwhile IMDX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About SYBX vs IMDX
SYBX
Head-to-Head Winner
Synlogic, Inc. Common Stock
$0.56
-50.0% 1D
Market Cap
$13.1M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.68β · 173% Vol
Unified Composite Score
34.6
SELL
Tech 40.0
Fund 44.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Markdown · Sell / avoid
IMDX
Insight Molecular Diagnostics Inc. Common Stock
$1.66
+4.4% 1D
Market Cap
$52.1M
TTM Revenue
$2.0M
Forward P/E
N/M
Beta / 30D Vol
2.91β · 76% Vol
Unified Composite Score
45.5
HOLD
Tech 50.0
Fund 40.0
Flow 58.0
Mom 40.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (SYBX 2 – 3 IMDX)
1. Valuation Multiples
IMDX
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
18.8x
2. Growth & Scale
IMDX
Revenue Growth (YoY)
-100.0%
+115.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$2.0M
Market Cap
$13.1M
$52.1M
3. Profitability & Quality
SYBX
Gross Margin
N/A
55.6%
Operating Margin
0.0%
-1883.2%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-27.5%
-23603.1%
4. Balance Sheet & Cash Flow
IMDX
Cash Generation (TTM)
-$3.3M
-$31M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$0.88 Book/Sh · -27.5% ROE
$15M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
SYBX
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
N/A (N/A)
99.4% (12th %ile)
Put/Call OI Skew
N/A
0.08x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SYBX (2) vs IMDX (5)| Institutional Metric | SYBX | IMDX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $13.1M | $52.1M | IMDX | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -100.0% | +115.0% | IMDX | |
| Operating Margin (TTM) | 0.0% | -1883.2% | SYBX | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -27.5% | -23603.1% | SYBX | |
| 52-Week Range Position | 0% ($1–$2) | 3% ($2–$8) | IMDX | |
| Beta / 30D Volatility | 1.68β · 173% Vol | 2.91β · 76% Vol | IMDX | |
| Unified Institutional Score | 34.6 / 100 (SELL) | 45.5 / 100 (HOLD) | IMDX | |
| Trailing 12M Revenue (USD) | N/A | $2.0M | Scale | |
| Gross Profit Margin (TTM) | N/A | 55.6% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 18.8x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$3.3M ($0.88 Book/Sh · -27.5% ROE) | -$31M ($15M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
IMDX +78.63 pp
3M Horizon
IMDX +63.22 pp
6M Horizon
IMDX +63.22 pp
1Y Horizon
IMDX +63.22 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SYBX Revenue | IMDX Revenue | SYBX Op. Margin | IMDX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -2032.9% | N/A | SYBX |
| FY2019 | $0M | N/A | -2446.4% | N/A | SYBX |
| FY2020 | $0M | $0M | -11094.7% | -2443.3% | IMDX |
| FY2021 | $0M | $0M | -3464.4% | -2444.3% | IMDX |
| FY2022 | $0M | $0M | -5713.5% | -1878.6% | IMDX |
| FY2023 | $0M | $0M | -1636.3% | -1672.4% | SYBX |
| FY2024 | $0M | $0M | -511875.0% | -3245.1% | IMDX |
| FY2025 | N/A | $0M | N/A | -1260.8% | IMDX |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
SYBX
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact SYBX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
IMDX
BREAKDOWN
Current IV
99.4%
IV Percentile
12th %ile
Put/Call OI Skew
0.08x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact IMDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
SYBX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
IMDX Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ SYBX vs IMDX Key Questions & Quantitative Answers
As of Nov 19, 2026, Synlogic, Inc. (SYBX) captures the overall head-to-head institutional edge over Insight Molecular Diagnostics Inc. (IMDX) on higher Unified Composite conviction (34.6/100 SELL vs. 45.5/100 HOLD) after splitting the core matrix 2–5 (led by Profitability & Quality, Options & Positioning), while IMDX wins 3–2 across the 6-pillar growth and valuation breakdown. SYBX trades at $0.56 (N/M Forward P/E, 0.0% operating margin) versus IMDX at $1.66 (N/M Forward P/E, -1883.2% operating margin). Composite vs. Pillar Nuance: While IMDX currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. SYBX 34.6/100 SELL), SYBX captures the overall institutional head-to-head verdict (2–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -1883.2% operating margin) and revenue trajectory (-100.0% vs. +115.0% YoY). Technical & Structure Timing Caution: SYBX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 16.7); meanwhile IMDX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IMDX leads the Growth & Scale pillar: SYBX posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with IMDX at +115.0% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (55.6% gross margin, -1883.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SYBX cumulative revenue shifted N/A while IMDX shifted N/A. In operating R&D and SG&A reinvestment, SYBX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IMDX.
IMDX screens cheaper on headline valuation multiples. SYBX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas IMDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYBX (-27.5% ROE) versus IMDX (-23603.1% ROE) capital efficiency.
In options market volatility and institutional positioning, SYBX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.68β · 173% Vol realized risk). By comparison, IMDX carries 99.4% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.91β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
IMDX vs SYBX · Reverse Pair
SYBX vs ASMB
· Sector Peer
SYBX vs ELOX
· Sector Peer
SYBX vs SLDB
· Sector Peer
IMDX vs VTVT
· Sector Peer
IMDX vs AKTX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem